BioSpace News Archive

ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, published its Half Year 2023 Financial Statements.

ONWARD Medical N.V., the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury, announces the successful first-in-human implant of its ARC-IM Stimulator*, to restore upper extremity function after SCI.

Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell progenitor therapy platform to fully and rapidly re-arm the immune system, announced that the first patients have been dosed in its ReSET-02 Phase I/II trial for adult acute leukemia and myelodysplasia syndrome patients.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announced the appointment of Robert Lyne as Chief Portfolio Officer.

Accelerator Life Science Partners announced the Series A financing of Automera, a new biotechnology company that focuses on the development of autophagy-targeting chimera small molecules.

XNK Therapeutics AB announced that two posters, regarding bladder cancer and acute myeloid leukemia respectively, was presented at the 20th Meeting of the Society for Natural Immunity in Oslo, Norway, in September.

Ono Pharmaceutical Co., Ltd. announced that it has entered into a drug discovery collaboration agreement with Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, to discover and develop innovative antibody drugs in the oncology field.

IDEAYA Biosciences, Inc. announces that the U.S. FDA has granted Fast Track designation to IDEAYA’s development program investigating IDE161.

Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced a grant award up to $3.0 million for the development of a Group B Streptococcus vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health.

Kurin, Inc. has been named the 2023 Diverse Supplier of the Year by Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company.